Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Ultra-hypofractionation was non-inferior to conventional fractionation regarding 5-year failure-free survival and toxicity. The HYPO-RT-PC trial was done in 12 centres in Sweden and Denmark. In seven of ten bowel symptoms or problems the proportion of patients with clinically relevant deteriorations at the end of radiotherapy was significantly higher in the ultra-hyp fractionation group.
